The difference between filgotinib and upadatinib

Filgotinib (Filgotinib) and upadacitinib (Upadacitinib) are both drugs used to treat rheumatoid arthritis. Both are JAK kinase inhibitors, but they have some differences in their mechanisms of action, approved indications, safety and side effects. Patients need to choose to use filgotinib and upadatinib for treatment under the guidance of a doctor.

1. Mechanism of action: Figotinib is a JAK kinase inhibitor that mainly reduces inflammation and arthritis symptoms by inhibiting the JAK1 signaling pathway. Upadatinib is also a JAK kinase inhibitor , but its effect is broader than that of filgotinib, inhibiting both the JAK1 and JAK3 signaling pathways.

2. Indications: Currently, filgotinib has been approved for the treatment of adults with active rheumatoid arthritisand ulcerative colitis (UC);and upadatinib has not only been approved for the treatment of adults with active rheumatoid arthritis, but has also been approved for the treatment of other autoimmune diseases, such as psoriatic arthritis and intestinal inflammatory diseases.

3. Safety and side effects: There are some differences in side effects and safety between these two drugs. For example, filgotinib showed adverse risks of nausea, upper respiratory tract infection, urinary tract infection, and dizziness in clinical trials, while upadatinib may cause hypertension and dyslipidemia. In addition, the side effects and safety of various drugs need to be evaluated based on individual circumstances.

The original drug filgotinib has not yet been launched in China, and therefore is not included in medical insurance. The Bangladeshi version of the filgotinitine generic drug currently on the market overseas, specifications100mg*30 tablets may cost more than 500 yuan per box (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.